{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:20:17Z","timestamp":1792664417641,"version":"4.5.0"},"reference-count":64,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    Rosacea is a chronic inflammatory skin condition that affects over 5% of individuals worldwide. Its clinical presentation is characterized by an array of features, including erythema, papules and pustules, phymatous changes, telangiectasia, and ocular manifestations. Specifically, the multifaceted manifestation of erythema varies widely in intensity and distribution. Factors contributing to pathogenesis include neurovascular dysregulation, increased levels of pro-inflammatory mediators, and aberrant vasodilation. Erythema management plays an important role in reducing the psychosocial burden associated with rosacea and improving overall quality of life. Cochrane CENTRAL, Medline, and Embase databases were searched from inception to September 2023 and included 33 clinical trials reporting on a total of 7411 rosacea patients (74.1% female) and 21 different topical or systemic treatments. The mean age was 48.8\u2009years (range, 18-83\u2009years), and the mean time to outcome assessment was 8.1\u2009weeks (standard deviation, 4.1\u2009weeks). Treatment efficacy was assessed by outcome measures including percent improvement from baseline on 4- and 5-point scales, clinician erythema assessment (CEA) success (improvement \u22651 point), and CEA and patient self-assessment success (improvement \u22651 point). Pooled effect sizes for each treatment were calculated as a weighted average based on the number of patients in each study. The most effective topical treatments for reducing erythema include sodium sulphacetamide and sulphur, praziquantel, metronidazole, and B244 spray (\n                    <jats:italic toggle=\"yes\">Nitrosomonas eutropha<\/jats:italic>\n                    ). The most effective systemic treatment was paroxetine. Our findings highlight the varying efficacy of treatments in addressing the erythema in rosacea, recognizing the nuances of clinical presentations.\n                  <\/jats:p>","DOI":"10.1177\/12034754241287546","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T03:35:11Z","timestamp":1730345711000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Treatments in Reducing Facial Erythema in Rosacea: A Systematic Review"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8503-0056","authenticated-orcid":false,"given":"Nicholas J.","family":"Hua","sequence":"first","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chen","sequence":"additional","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-095X","authenticated-orcid":false,"given":"Ryan S. Q.","family":"Geng","sequence":"additional","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Gary","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health &amp; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Farshchian M Daveluy S. Rosacea. In: StatPearls. StatPearls Publishing; 2023:1-2. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557574\/"},{"issue":"6","key":"e_1_3_3_3_2","first-page":"348","article-title":"Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life","volume":"6","author":"Huynh TT.","year":"2013","unstructured":"Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits. 2013;6(6):348-354.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_2983_22"},{"issue":"3","key":"e_1_3_3_5_2","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1","volume":"5","author":"Del Rosso JQ","year":"2012","unstructured":"Del Rosso JQ. Advances in understanding and managing rosacea: part 1. J Clin Aesthet Dermatol. 2012;5(3):16-25.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1122134"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S126850"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-021-02305-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00461-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-020-03200-1"},{"issue":"1","key":"e_1_3_3_12_2","first-page":"38","article-title":"Rosacea: a review","volume":"34","author":"Culp B","year":"2009","unstructured":"Culp B, Scheinfeld N. Rosacea: a review. P T. 2009;34(1):38.","journal-title":"P T"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31735"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1610549"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70085-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02940.x"},{"key":"e_1_3_3_18_2","first-page":"54","article-title":"A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea","volume":"96","author":"Draelos ZD","year":"2015","unstructured":"Draelos ZD, Elewski BE, Harper JC, et al A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015;96:54-61.","journal-title":"Cutis"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030051008"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03427.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-001-0144-4"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2010.541398"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13801"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13177"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02589.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639709160276"},{"key":"e_1_3_3_29_2","unstructured":"EudraCT Number 2006-003707-40\u2014Clinical trial results\u2014EU Clinical Trials Register. Cited December 14 2023. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-003707-40\/results"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb03972.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16254"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.043"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12552"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14347"},{"key":"e_1_3_3_35_2","unstructured":"AOBiome LLC. A vehicle-controlled double-blind randomized phase II study of B244 delivered as a topical spray to determine safety and efficacy in subjects with mild to moderate rosacea. clinicaltrials.gov; 2022."},{"key":"e_1_3_3_36_2","unstructured":"CTG Labs\u2014NCBI. Cited December 14 2023. https:\/\/clinicaltrials.gov\/study\/NCT01174030"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.050"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.028"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12520"},{"issue":"6","key":"e_1_3_3_40_2","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","unstructured":"Fowler J, Jackson M, Moore A, et al Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-656.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_41_2","unstructured":"EudraCT Number 2012-001044-22\u2014Clinical trial results\u2014EU Clinical Trials Register. Cited December 14 2023. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-001044-22\/results"},{"key":"e_1_3_3_42_2","unstructured":"Phase 3 efficacy and safety study of CD07805\/47 topical gel in subjects with facial erythema associated with rosacea. Cited December 14 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01355471"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.037"},{"key":"e_1_3_3_44_2","unstructured":"Efficacy and safety of AGN-199201 in patients with persistent erythema associated with rosacea. Cited December 14 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02131636"},{"key":"e_1_3_3_45_2","unstructured":"Safety and efficacy of oxymetazoline HCl cream 1.0% in patients with persistent erythema associated with rosacea. Cited December 14 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02132117"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S50804"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S282396"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02097-z"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19732"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-020-00777-5"},{"key":"e_1_3_3_51_2","unstructured":"Shrestha P Fariba KA Abdijadid S. Paroxetine. In: StatPearls. StatPearls Publishing; 2024;1-4. Cited June 25 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526022\/"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00004"},{"issue":"4","key":"e_1_3_3_53_2","first-page":"427","article-title":"The use of sulfur in dermatology","volume":"3","author":"Gupta AK","year":"2004","unstructured":"Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol. 2004;3(4):427-431.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"e_1_3_3_54_2","first-page":"128","article-title":"The use of sodium sulfacetamide in dermatology","volume":"96","author":"Wolf K","year":"2015","unstructured":"Wolf K, Silapunt S. The use of sodium sulfacetamide in dermatology. Cutis. 2015;96(2):128-130.","journal-title":"Cutis"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s3630"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2019.00517"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000446215"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15652"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02125.x"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.8.0010"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08028.x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2020.04.011"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00595-7"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754050-00003"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102002"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241287546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754241287546","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241287546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:51:09Z","timestamp":1777391469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754241287546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/12034754241287546"],"URL":"https:\/\/doi.org\/10.1177\/12034754241287546","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}